Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Clinical trial NCT03485547 · COMPLETED
Trial details
- NCT number
- NCT03485547
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-23
- Primary completion
- 2022-01-10
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.